SPOTLIGHT: Inhibitex raising $41M

Inhibitex plans to raise $41 million through a private placement of 5 million shares. The money will go to develop Veronate, further advance its Aurexis clinical program and fund the company's preclinical and research programs. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.